- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
ClinicalTrials.gov registry snapshot / 2026-07-24Peptide trials,
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Official registry finder
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
31matching registry records
Snapshot timestampJuly 24, 2026 at 9:00 AM UTC
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444 / Boehringer Ingelheim | RecruitingVerified 2026-07 | Phase 31,800 estimated | 430 recruiting525 listed / 36 countries | Dec 27, 2031estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT06632444 ↗ |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisNCT06632457 / Boehringer Ingelheim | RecruitingVerified 2026-07 | Phase 31,590 estimated | 343 recruiting444 listed / 36 countries | Jun 5, 2029estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT06632457 ↗ |
| A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyNCT07407348 / Boehringer Ingelheim | RecruitingVerified 2026-06 | Phase 180 estimated | 1 recruiting1 listed / 1 countries | Jan 26, 2027estimated | Jun 16, 2026ClinicalTrials.gov | Open NCT07407348 ↗ |
| Albuminuria Reduction Study With Survodutide Treatment in Kidney DiseaseNCT07206290 / ARTIST-CKD / University Medical Center Groningen | Not yet recruitingVerified 2025-08 | Phase 2120 estimated | 0 recruiting0 listed / 0 countries | Nov 30, 2027estimated | Oct 3, 2025ClinicalTrials.gov | Open NCT07206290 ↗ |
| A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverNCT05202353 / Boehringer Ingelheim | Active, not recruitingVerified 2026-07 | Phase 129 actual | 0 recruiting1 listed / 1 countries | Dec 2, 2026estimated | Jul 22, 2026ClinicalTrials.gov | Open NCT05202353 ↗ |
| A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityNCT06745284 / Boehringer Ingelheim | Active, not recruitingVerified 2026-05 | Phase 164 actual | 0 recruiting2 listed / 1 countries | Jan 8, 2027estimated | May 12, 2026ClinicalTrials.gov | Open NCT06745284 ↗ |
| A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyNCT07221591 / Boehringer Ingelheim | Active, not recruitingVerified 2026-03 | Phase 1100 actual | 0 recruiting2 listed / 1 countries | Aug 4, 2026estimated | Mar 13, 2026ClinicalTrials.gov | Open NCT07221591 ↗ |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male VolunteersNCT03175211 / Boehringer Ingelheim | CompletedVerified 2018-02 | Phase 120 actual | 0 recruiting1 listed / 1 countries | Feb 19, 2018actual | Jul 16, 2018ClinicalTrials.gov | Open NCT03175211 ↗ |
| A Study to Test Different Doses of BI 456906 in Patients With ObesityNCT03591718 / Boehringer Ingelheim | CompletedVerified 2021-03 | Phase 1131 actual | 0 recruiting2 listed / 1 countries | Apr 20, 2020actual | Mar 22, 2021ClinicalTrials.gov | Open NCT03591718 ↗ |
| A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.NCT04153929 / Boehringer Ingelheim | CompletedVerified 2022-11Registry results posted | Phase 2413 actual | 0 recruiting80 listed / 14 countries | Oct 8, 2021actual | Nov 29, 2022ClinicalTrials.gov | Open NCT04153929 ↗ |
| A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2NCT04384081 / Boehringer Ingelheim | CompletedVerified 2021-01 | Phase 137 actual | 0 recruiting1 listed / 1 countries | Nov 17, 2020actual | Jan 26, 2021ClinicalTrials.gov | Open NCT04384081 ↗ |
| A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightNCT04667377 / Boehringer Ingelheim | CompletedVerified 2023-10Registry results posted | Phase 2387 actual | 0 recruiting43 listed / 12 countries | Sep 15, 2022actual | Nov 2, 2023ClinicalTrials.gov | Open NCT04667377 ↗ |
| A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)NCT04771273 / Boehringer Ingelheim | CompletedVerified 2024-11Registry results posted | Phase 2295 actual | 0 recruiting154 listed / 25 countries | Nov 9, 2023actual | Dec 3, 2024ClinicalTrials.gov | Open NCT04771273 ↗ |
| A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906NCT05296733 / Boehringer Ingelheim | CompletedVerified 2024-08 | Phase 182 actual | 0 recruiting13 listed / 6 countries | Dec 29, 2023actual | Aug 15, 2024ClinicalTrials.gov | Open NCT05296733 ↗ |
| A Study in Healthy Men to Test How BI 456906 is Processed in the BodyNCT05421338 / Boehringer Ingelheim | CompletedVerified 2022-12 | Phase 16 actual | 0 recruiting1 listed / 1 countries | Nov 17, 2022actual | Dec 14, 2022ClinicalTrials.gov | Open NCT05421338 ↗ |
| A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906NCT05751226 / Boehringer Ingelheim | CompletedVerified 2025-01 | Phase 188 actual | 0 recruiting1 listed / 1 countries | Aug 1, 2024actual | Jan 22, 2025ClinicalTrials.gov | Open NCT05751226 ↗ |
| A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the BloodNCT05896384 / Boehringer Ingelheim | CompletedVerified 2025-04 | Phase 132 actual | 0 recruiting1 listed / 1 countries | Feb 14, 2025actual | Apr 16, 2025ClinicalTrials.gov | Open NCT05896384 ↗ |
| A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT06066515 / SYNCHRONIZE™-1 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 3726 actual | 0 recruiting118 listed / 14 countries | Dec 2, 2025actual | Mar 12, 2026ClinicalTrials.gov | Open NCT06066515 ↗ |
| A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightNCT06066528 / SYNCHRONIZE™-2 / Boehringer Ingelheim | CompletedVerified 2026-06 | Phase 3755 actual | 0 recruiting143 listed / 19 countries | Dec 12, 2025actual | Jun 24, 2026ClinicalTrials.gov | Open NCT06066528 ↗ |
| A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 / Boehringer Ingelheim | CompletedVerified 2026-07 | Phase 35,531 actual | 0 recruiting540 listed / 35 countries | Jun 1, 2026actual | Jul 23, 2026ClinicalTrials.gov | Open NCT06077864 ↗ |
| A Study to Test Whether Survodutide Helps Japanese People Living With Obesity DiseaseNCT06176365 / SYNCHRONIZE™JP / Boehringer Ingelheim | CompletedVerified 2026-04 | Phase 3274 actual | 0 recruiting28 listed / 1 countries | Dec 3, 2025actual | Apr 30, 2026ClinicalTrials.gov | Open NCT06176365 ↗ |
| A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or ObesityNCT06200467 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 1110 actual | 0 recruiting1 listed / 1 countries | Oct 22, 2025actual | Mar 13, 2026ClinicalTrials.gov | Open NCT06200467 ↗ |
| A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose WeightNCT06214741 / Boehringer Ingelheim | CompletedVerified 2026-04 | Phase 3307 actual | 0 recruiting28 listed / 1 countries | Jul 29, 2025actual | Apr 30, 2026ClinicalTrials.gov | Open NCT06214741 ↗ |
| A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)NCT06309992 / Boehringer Ingelheim | CompletedVerified 2026-04 | Phase 3218 actual | 0 recruiting37 listed / 2 countries | Oct 9, 2025actual | Apr 30, 2026ClinicalTrials.gov | Open NCT06309992 ↗ |
| A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney ProblemsNCT06352411 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 142 actual | 0 recruiting2 listed / 1 countries | Sep 16, 2025actual | Mar 13, 2026ClinicalTrials.gov | Open NCT06352411 ↗ |
| A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain ActivityNCT06352424 / Boehringer Ingelheim | CompletedVerified 2025-03 | Phase 123 actual | 0 recruiting1 listed / 1 countries | Feb 24, 2025actual | Mar 12, 2025ClinicalTrials.gov | Open NCT06352424 ↗ |
| A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the BodyNCT06492135 / Boehringer Ingelheim | CompletedVerified 2025-04 | Phase 130 actual | 0 recruiting1 listed / 1 countries | Apr 15, 2025actual | Apr 23, 2025ClinicalTrials.gov | Open NCT06492135 ↗ |
| A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or ObesityNCT06564441 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 134 actual | 0 recruiting1 listed / 1 countries | Dec 16, 2025actual | Mar 13, 2026ClinicalTrials.gov | Open NCT06564441 ↗ |
| A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the BodyNCT06772532 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 130 actual | 0 recruiting1 listed / 1 countries | May 29, 2025actual | Mar 13, 2026ClinicalTrials.gov | Open NCT06772532 ↗ |
| A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the BodyNCT07071974 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 116 actual | 0 recruiting1 listed / 1 countries | Oct 7, 2025actual | Mar 13, 2026ClinicalTrials.gov | Open NCT07071974 ↗ |
| A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like InjectorNCT07413913 / Boehringer Ingelheim | CompletedVerified 2026-06 | Phase 156 actual | 0 recruiting1 listed / 1 countries | May 28, 2026actual | Jun 15, 2026ClinicalTrials.gov | Open NCT07413913 ↗ |
Recruiting location footprint
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Clinical trial finder FAQ
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
Evidence boundary
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →